On April 1, 2019 Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that pre-clinical data on its oncolytic immunotherapy platform will be presented at a poster session today at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019 being held in Atlanta, Georgia (Press release, Replimune, APR 1, 2019, View Source [SID1234534884]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The pre-clinical data to be presented in this poster reiterates the ability of our platform to provide a potent and versatile approach to developing new therapies intended to maximally activate a patient’s immune system against their own cancer," commented Robert Coffin, Ph.D., co-founder, President and CEO of Replimune. "This data supports the clinical development of our advancing pipeline of oncolytic immunotherapies, including our lead product candidate, RP1, and RP2 which additionally encodes an anti-CTLA-4 antibody."
Details of Replimune’s poster presentation:
Abstract Title: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1 (Abstract #3136)
Session Date and Time: Monday April 1, 2019, 8:00AM – 12:00PM
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 22
The poster will be made available on the company’s website from the time of presentation.
Abstracts and full session details can be found at www.aacr.org